Literature DB >> 9259401

Tumor-infiltrating dendritic cells are defective in their antigen-presenting function and inducible B7 expression in rats.

P Chaux1, N Favre, M Martin, F Martin.   

Abstract

Tumors are tolerated by the immune system notwithstanding the expression of tumor-associated antigens. PROb tumor cells, derived from a rat colon carcinoma, are rejected by tumor-immune hosts but give rise to progressive tumors in naive hosts. Paradoxically, these tumors are heavily infiltrated by dendritic cells that express MHC class II and ICAM-1. These tumor-infiltrating dendritic cells (TiDCs) could be expected to process and present to T cells the antigens released by the adjacent tumor cells. Indeed, we report here that TiDCs, compared with splenic dendritic cells, are poor stimulators of primary allogeneic T-cell proliferation and cytokine [interleukin-2 (IL-2) and interferon-gamma] production. Most of them (89-97%) do not express B7, an essential co-stimulatory signal for T cells, even after a culture period allowing B7 up-regulation on epidermal Langerhans cells. GM-CSF in association with tumor necrosis factor-alpha or IL-4, or cell-associated CD40-ligand, all known to be potent stimulators of B7 expression on other dendritic cells, did not restore B7 expression by TiDCs. After a first exposure to TiDCs, allogeneic T-cell response to a second challenge to splenic dendritic cells was decreased. The failure of most dendritic cells infiltrating PROb tumors to express B7, even after stimulation, may contribute to their poor capacity to stimulate T cells and could play a role in the immune tolerance allowing tumor growth.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259401     DOI: 10.1002/(sici)1097-0215(19970807)72:4<619::aid-ijc12>3.0.co;2-6

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  24 in total

1.  Effects of glioma cells on maturation of dendritic cells.

Authors:  Tetsuro Kikuchi; Toshiaki Abe; Tsuneya Ohno
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

2.  Relationship between the in vitro response of dendritic cells to Lactobacillus and prevention of tumorigenesis in the mouse.

Authors:  Akimitsu Takagi; Haruo Ikemura; Takeshi Matsuzaki; Mikiko Sato; Koji Nomoto; Masami Morotomi; Teruo Yokokura
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

3.  Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways.

Authors:  Sreenivas Laxmanan; Stuart W Robertson; Enfeng Wang; Julie S Lau; David M Briscoe; Debabrata Mukhopadhyay
Journal:  Biochem Biophys Res Commun       Date:  2005-08-19       Impact factor: 3.575

Review 4.  Immunosuppressive strategies that are mediated by tumor cells.

Authors:  Gabriel A Rabinovich; Dmitry Gabrilovich; Eduardo M Sotomayor
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

Review 5.  Mast cells as regulators of adaptive immunity to tumours.

Authors:  A Wasiuk; V C de Vries; K Hartmann; A Roers; R J Noelle
Journal:  Clin Exp Immunol       Date:  2008-12-05       Impact factor: 4.330

Review 6.  IDO-expressing regulatory dendritic cells in cancer and chronic infection.

Authors:  Alexey Popov; Joachim L Schultze
Journal:  J Mol Med (Berl)       Date:  2007-09-18       Impact factor: 4.599

7.  CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer.

Authors:  Stephan Roux; Lionel Apetoh; Fanny Chalmin; Sylvain Ladoire; Grégoire Mignot; Pierre-Emmanuel Puig; Gregoire Lauvau; Laurence Zitvogel; François Martin; Bruno Chauffert; Hideo Yagita; Eric Solary; François Ghiringhelli
Journal:  J Clin Invest       Date:  2008-10-01       Impact factor: 14.808

8.  Mechanisms of ganglioside inhibition of APC function.

Authors:  Sheila Caldwell; Andreas Heitger; Weiping Shen; Yihui Liu; Barbara Taylor; Stephan Ladisch
Journal:  J Immunol       Date:  2003-08-15       Impact factor: 5.422

9.  Regulatory dendritic cells: there is more than just immune activation.

Authors:  Susanne V Schmidt; Andrea C Nino-Castro; Joachim L Schultze
Journal:  Front Immunol       Date:  2012-09-04       Impact factor: 7.561

10.  Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.

Authors:  Laura Ridolfi; Massimiliano Petrini; Anna Maria Granato; Giusy Gentilcore; Ester Simeone; Paolo Antonio Ascierto; Elena Pancisi; Valentina Ancarani; Laura Fiammenghi; Massimo Guidoboni; Francesco de Rosa; Linda Valmorri; Emanuela Scarpi; Stefania Vittoria Luisa Nicoletti; Stefano Baravelli; Angela Riccobon; Ruggero Ridolfi
Journal:  J Transl Med       Date:  2013-05-31       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.